Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Shulman

Showing results (161-170 of 282) with videos related to

Pageof 29
Sort By:
Plos One|May 27, 2022
Oncologist phenotypes and associations with response to a machine learning-based intervention to increase advance care planning: Secondary analysis of a randomized clinical trialEric Li, Christopher Manz, Manqing Liu, et al.
JCO Global Oncology|June 8, 2023
Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and OpportunitiesLynne Davies, Danny A Milner, Lawrence N Shulman, et al.
Public Health Action|September 25, 2015
Caring for patients with surgically resectable cancers: experience from a specialised centre in rural RwandaJ M Mubiligi, B Hedt-Gauthier, T Mpunga, et al.
BMC Cancer|June 6, 2018
Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of ExcellenceJean Marie Vianney Dusengimana, Vedaste Hategekimana, Ryan Borg, et al.
JAMA Network Open|October 25, 2023
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer SurvivalMarla Lipsyc-Sharf, Karla V Ballman, Jordan D Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancerP A Vasey, L N Shulman, S Campos, et al.
Cancer|January 5, 1999
Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinomaA L Abner, L Collins, G Peiro, et al.
Blood|May 1, 1996
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcomeP M Mauch, L A Kalish, K C Marcus, et al.
JAMA Network Open|July 9, 2021
Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment InitiationZachary A K Frosch, Nicholas Illenberger, Nandita Mitra, et al.
Seminars in Oncology|August 1, 1995
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancerG M Strauss, T J Lynch, A D Elias, et al.
Pageof 29

Showing results (161-170 of 282) with videos related to

Sort By:
Pageof 29
Plos One|May 27, 2022
Oncologist phenotypes and associations with response to a machine learning-based intervention to increase advance care planning: Secondary analysis of a randomized clinical trialEric Li, Christopher Manz, Manqing Liu, et al.
JCO Global Oncology|June 8, 2023
Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and OpportunitiesLynne Davies, Danny A Milner, Lawrence N Shulman, et al.
Public Health Action|September 25, 2015
Caring for patients with surgically resectable cancers: experience from a specialised centre in rural RwandaJ M Mubiligi, B Hedt-Gauthier, T Mpunga, et al.
BMC Cancer|June 6, 2018
Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of ExcellenceJean Marie Vianney Dusengimana, Vedaste Hategekimana, Ryan Borg, et al.
JAMA Network Open|October 25, 2023
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer SurvivalMarla Lipsyc-Sharf, Karla V Ballman, Jordan D Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancerP A Vasey, L N Shulman, S Campos, et al.
Cancer|January 5, 1999
Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinomaA L Abner, L Collins, G Peiro, et al.
Blood|May 1, 1996
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcomeP M Mauch, L A Kalish, K C Marcus, et al.
JAMA Network Open|July 9, 2021
Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment InitiationZachary A K Frosch, Nicholas Illenberger, Nandita Mitra, et al.
Seminars in Oncology|August 1, 1995
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancerG M Strauss, T J Lynch, A D Elias, et al.
Pageof 29